clobazam has been researched along with Abdominal Epilepsy in 20 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effectiveness of monotherapy clobazam (CLB) to carbamazepine (CBZ) and phenytoin (PHT) in children with epilepsy." | 9.08 | Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. ( , 1998) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset focal or generalized seizures." | 8.98 | Clobazam monotherapy for focal or generalized seizures. ( Anand, V; Arya, R; Garg, SK; Giridharan, N, 2018) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset partial or generalized seizures." | 8.90 | Clobazam monotherapy for partial-onset or generalized-onset seizures. ( Anand, V; Arya, R; Garg, SK; Michael, BD, 2014) |
| "A 11 year-old boy with tuberous sclerosis complex and left frontal refractory epilepsy, evaluated within a paediatric epilepsy surgery program." | 5.42 | [Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous sclerosis]. ( Blanco-Beregana, M; Budke, M; Fournier-Del Castillo, MC; Garcia-Fernandez, M; Garcia-Penas, JJ; Melero-Llorente, J; Perez-Jimenez, MÁ; Robles-Bermejo, F, 2015) |
| "To compare the effectiveness of monotherapy clobazam (CLB) to carbamazepine (CBZ) and phenytoin (PHT) in children with epilepsy." | 5.08 | Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. ( , 1998) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset focal or generalized seizures." | 4.98 | Clobazam monotherapy for focal or generalized seizures. ( Anand, V; Arya, R; Garg, SK; Giridharan, N, 2018) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset partial or generalized seizures." | 4.90 | Clobazam monotherapy for partial-onset or generalized-onset seizures. ( Anand, V; Arya, R; Garg, SK; Michael, BD, 2014) |
| "Clobazam (CLB) has an important antiepileptic effect and is less expensive than the new antiepileptic drugs (AEDs), but still has not been considered as first-line drug in the treatment of epilepsy." | 2.70 | Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. ( Carvalho, MI; Cendes, F; Guerreiro, CA; Marques, LH; Montenegro, MA; Mory, SB; Noronha, AL, 2001) |
| "Gabapentin was started at 400 mg/day and was individually titrated to effective tolerable dose up to 2400 mg/day." | 2.69 | Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice. ( Bruni, J, 1998) |
| "The effect of 1,5-benzodiazepine clobazam was assessed in a double-blind add-on trial in 20 patients with chronic complex partial seizures uncontrolled by maximally tolerable daily dosage of standard antiepileptic drug therapy." | 2.66 | Clobazam for refractory focal epilepsy. A controlled trial. ( Roeder-Wanner, U; Rohde, M; Schmidt, D; Wolf, P, 1986) |
| "A 11 year-old boy with tuberous sclerosis complex and left frontal refractory epilepsy, evaluated within a paediatric epilepsy surgery program." | 1.42 | [Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous sclerosis]. ( Blanco-Beregana, M; Budke, M; Fournier-Del Castillo, MC; Garcia-Fernandez, M; Garcia-Penas, JJ; Melero-Llorente, J; Perez-Jimenez, MÁ; Robles-Bermejo, F, 2015) |
| "Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies." | 1.33 | Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. ( da Silveira, MR; Franzon, RC; Guerreiro, CA; Guerreiro, MM; Montenegro, MA, 2006) |
| "Three patients aged 16, 19, and 65 years with a 13- to 36-year history of partial epilepsy were receiving a therapeutic dosage of carbamazepine or phenobarbital plus either clobazam (CLB) or valproate (VPA)." | 1.30 | Negative myoclonic status due to antiepileptic drug tapering: report of three cases. ( Aguglia, U; Gambardella, A; Oliveri, RL; Quattrone, A; Russo, C; Zappia, M, 1997) |
| "Carbamazepine has no effect on the EEG, in epilepsies with atypical course (atypical benign partial epilepsy, Landau-Kleffner syndrome, epilepsy with continuous spikes and waves during slow sleep [CSWS]) carbamazepine usually has no effect either on the seizures or on the EEG, on the contrary, in some cases both may even get worse." | 1.29 | Treatment of "benign" partial epilepsies of childhood, including atypical forms. ( Gross-Selbeck, G, 1995) |
| "Clobazam was given in addition to conventional antiepileptic therapy, beginning with a dose of 20 mg at night." | 1.27 | Clobazam in the treatment of epilepsy. ( Bury, R; Fullinfaw, R; Kilpatrick, C; Moulds, R, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gimigliano, F | 1 |
| Arya, R | 2 |
| Giridharan, N | 1 |
| Anand, V | 2 |
| Garg, SK | 2 |
| Imataka, G | 1 |
| Noguchi, M | 1 |
| Tsukada, K | 1 |
| Takahashi, T | 1 |
| Yamanouchi, H | 1 |
| Arisaka, O | 1 |
| Tanaka, S | 1 |
| Tanaka, T | 1 |
| Michael, BD | 1 |
| Fournier-Del Castillo, MC | 1 |
| Melero-Llorente, J | 1 |
| Blanco-Beregana, M | 1 |
| Robles-Bermejo, F | 1 |
| Budke, M | 1 |
| Garcia-Fernandez, M | 1 |
| Garcia-Penas, JJ | 1 |
| Perez-Jimenez, MÁ | 1 |
| Héberlé, C | 1 |
| Berquin, P | 1 |
| Larnicol, N | 1 |
| Wallois, F | 1 |
| Iwasaki, T | 1 |
| Miura, H | 1 |
| Sunaoshi, W | 1 |
| Hosoda, N | 1 |
| Takei, K | 1 |
| Katayama, F | 1 |
| da Silveira, MR | 1 |
| Montenegro, MA | 2 |
| Franzon, RC | 1 |
| Guerreiro, CA | 2 |
| Guerreiro, MM | 1 |
| Dulac, O | 1 |
| Figueroa, D | 1 |
| Rey, E | 1 |
| Arthuis, M | 1 |
| Gross-Selbeck, G | 1 |
| Buchanan, N | 1 |
| Gambardella, A | 1 |
| Aguglia, U | 1 |
| Oliveri, RL | 1 |
| Russo, C | 1 |
| Zappia, M | 1 |
| Quattrone, A | 1 |
| Bruni, J | 1 |
| Contin, M | 1 |
| Riva, R | 1 |
| Albani, F | 1 |
| Baruzzi, AA | 1 |
| Cendes, F | 1 |
| Noronha, AL | 1 |
| Mory, SB | 1 |
| Carvalho, MI | 1 |
| Marques, LH | 1 |
| Guilloton, L | 1 |
| Burckard, E | 1 |
| Fresse, S | 1 |
| Drouet, A | 1 |
| Felten, D | 1 |
| Schmidt, D | 1 |
| Rohde, M | 1 |
| Wolf, P | 1 |
| Roeder-Wanner, U | 1 |
| Kilpatrick, C | 1 |
| Bury, R | 1 |
| Fullinfaw, R | 1 |
| Moulds, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
3 reviews available for clobazam and Abdominal Epilepsy
| Article | Year |
|---|---|
Is clobazam monotherapy effective and safe in people with focal or generalized seizures? A Cochrane Review summary with commentary.
Topics: Anticonvulsants; Clobazam; Epilepsies, Partial; Epilepsy, Generalized; Humans | 2020 |
Clobazam monotherapy for focal or generalized seizures.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsies, Par | 2018 |
Clobazam monotherapy for partial-onset or generalized-onset seizures.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsies, Par | 2014 |
5 trials available for clobazam and Abdominal Epilepsy
| Article | Year |
|---|---|
Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anti-Anxiety Agents; Anticonvulsants; | 1998 |
Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy.
Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; C | 1998 |
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Chil | 1999 |
Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Drug Admin | 2001 |
Clobazam for refractory focal epilepsy. A controlled trial.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clinical Trials as Topic | 1986 |
12 other studies available for clobazam and Abdominal Epilepsy
| Article | Year |
|---|---|
Partial epilepsy and developmental delay in infant with ring chromosome 14.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Chromosome Disorders; Chromosomes, Human, Pair 1 | 2013 |
Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy.
Topics: Adult; Anticonvulsants; Benzodiazepines; Clobazam; Drug Therapy, Combination; Epilepsies, Partial; E | 2013 |
[Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous sclerosis].
Topics: Acetamides; Anticonvulsants; Benzodiazepines; Child; Clobazam; Cognition Disorders; Dibenzazepines; | 2015 |
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep.
Topics: Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Combined Modali | 2002 |
[A case of intractable epilepsy showing frequent gelastic seizures by administration of clobazam].
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsies, Partial; Humans; Laughter; Male; | 2003 |
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Electroencephalogra | 2006 |
[Monotherapy with clobazam in epilepsies in children].
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child, | 1983 |
Treatment of "benign" partial epilepsies of childhood, including atypical forms.
Topics: Adrenocorticotropic Hormone; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinone | 1995 |
Clobazam in the treatment of epilepsy: prospective follow-up to 8 years.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; | 1993 |
Negative myoclonic status due to antiepileptic drug tapering: report of three cases.
Topics: Adolescent; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cerebral | 1997 |
[Epileptic crisis after antimalaria chemoprophylaxis with chloroquine].
Topics: Anti-Anxiety Agents; Anticonvulsants; Antimalarials; Benzodiazepines; Chloroquine; Clobazam; Epileps | 2001 |
Clobazam in the treatment of epilepsy.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinone | 1987 |